Prognostic significance of expression of CD133, VEGF and CD34 in hepatocellular carcinoma

Chinese Journal of Cancer Prevention and Treatment

Volumn 20, Issue 13, 2013, Pages 998-1002

  Wu, Li Ming ^a   Cheng, Cai Tao ^a   Chen, Xian Xiang ^a   Wang, Jiang Hua ^a   Liu, Hai Yan ^a   Tian, Lin ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Carcinoma, hepatocellular pathology; CD133; CD34; Immunohistochemistry; Liver neoplasms pathology; Prognosis; VEGF

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; VASCULOTROPIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MICROVASCULATURE; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84886926169     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001, 414(6859): 105-111.
2. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment[J]. J Pathol, 2008, 214(1): 3-9.
3. + liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling[J]. Hepatology, 2012, 55(3): 807-820.
4. Gentles AJ, Plevritis SK, Majeti R, et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia[J]. JAMA, 2010, 304(24): 2706-2715.
5. + liver cancer stem cells modulate radio resistance in human hepatocellular carcinoma[J]. Cancer Lett, 2012, 315(2): 129-137.
6. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells[J]. Gastroenterology, 2007, 132(7): 2542-2556.
7. 2011, 18(9): 693-696.
8. 2000, 29(4): 6-9.
9. Colombo F, Baldan F, Mazzucchelli S, et al. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma[J]. PLoS One, 2011, 6(6): e21369.
10. 2006, 14(1): 37-40.
11. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells[J]. Cancer Cell, 2007, 11(1): 69-82.
12. Yao XH, Ping YF, Chen JH, et al. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formlpeptide receptor FPR[J]. J Pathol, 2008, 215(4): 369-376.
13. Kohga K, Tatsumi T, Takehara T, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma[J]. J Hepato, 2010, 52(6): 872-879.
14. Sasaki A, Kamiyama T, Yokoo H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma[J]. Oncol Rep, 2010, 24(2): 537-546.
15. Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma [J]. Int J Clin Pract, 2008, 62(8): 1212-1218.
16. Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma[J]. Gut, 2010, 59(7): 953-962.